Esperion (NASDAQ: ESPR) today announced that it will host a virtual
research and development day, featuring Global Scientific Leaders
C. Michael Gibson, MS, MD, from Harvard Medical Research
Institutes, and Professor Peter Libby, MD, from Brigham and Women’s
Hospital and Harvard Medical School, who will discuss Esperion’s
discovery efforts and investigational programs.
Esperion research and development leadership will provide an
overview of its planned scientific focus and future growth drivers,
including the CLEAR Outcomes trial for bempedoic acid, oral PCSK9
inhibitor, and Next Generation ATP citrate lyase inhibition (ACLYi)
platform in people suffering from cardiovascular, hepatorenal and
metabolic diseases, inflammation, and oncology.
A live Q&A session will follow the formal
presentations. To register for the webinar, please
click here.
C. Michael Gibson, MS, MD is an interventional cardiologist,
cardiovascular researcher & educator. He is the CEO of the
combined non-profit Baim and PERFUSE research institutes at Harvard
Medical School. The institutes have led over 1,000 studies,
published 5,500 manuscripts, and have led 60 FDA submissions from
their network of 7,000 sites worldwide. His work has been cited
over 136,000 times.
Dr. Gibson has led phase 1-4 clinical trials, and cardiology
megatrials of over 15,000 patients which have led to the
international approval of drugs like prasugrel, rivaroxaban,
betrixaban and andexanet. He is currently leading HEARTLINE, the
first large “Virtual” trial of the Apple watch enrolling up to
180,000 patients, one of the largest randomized patient trials in
history. In addition, as an innovator, Dr. Gibson invented measures
of coronary blood flow that are widely used today.
Dr. Gibson founded clinicaltrialresults.org as well as
WikiDoc.org and WikiPatient.org, widely viewed open-source
textbooks of medicine. He is Editor-In-Chief of >2,200 active
contributors who have edited the content of over 100,000 chapters
over the past 15 years. Dr. Gibson is currently an at large member
of the FDA’s cardiorenal panel, having served as a standing member
from 2017 to 2021.
Dr. Gibson obtained his BS, MS, and MD degrees at the University
of Chicago where he was a Phi Beta Kappa and AOA graduate. He
completed his internship, residency and chief residency at the
Brigham and Women's Hospital and his cardiology fellowship at the
Beth Israel Deaconess Medical Center both at Harvard Medical
School.
Peter Libby, MD, a cardiovascular specialist at Brigham and
Women’s Hospital (BWH) in Boston, Massachusetts, holds the
Mallinckrodt Professorship of Medicine at Harvard Medical School.
He directed Cardiovascular Medicine at BWH from 1998 – 2014. His
areas of clinical expertise include general and preventive
cardiology and his major research focus is the role of inflammation
in vascular diseases such as atherosclerosis. Dr. Libby instigated
and helped to lead the large scale Canakinumab Anti-Inflammatory
Thrombosis Outcomes Trial that provided clinical validation of the
role of inflammation in atherosclerosis. He has also received
continuous funding from the US National Heart Lung and Blood
Institute (NHLBI) for several decades.
Dr. Libby has received numerous research awards, including the
Distinguished Scientist Award from the American College of
Cardiology (ACC), the Gold Medal of the European Society of
Cardiology, and the Ernst Jung Gold Medal for Medicine. Dr. Libby
is also a member of multiple professional organizations, including
the Association of American Physicians and the American Society for
Clinical Investigation. He currently serves as the president of the
International Atherosclerosis Society.
An author and lecturer on cardiovascular medicine and
atherosclerosis, Dr. Libby has published extensively in medical
journals including Circulation, Journal of Clinical Investigation,
Proceedings of the National Academy of Sciences, New England
Journal of Medicine, and Nature. He has held numerous visiting
professorships and delivered more than 150 major named or keynote
lectures throughout the world.
Dr. Libby earned his medical degree at the University of
California, San Diego, and completed his training in internal
medicine and cardiology at the Peter Bent Brigham Hospital (now
Brigham and Women’s Hospital). He also holds an honorary MA degree
from Harvard University, and three honorary doctorates.
CLEAR Cardiovascular Outcomes TrialCLEAR
Outcomes is a Phase 3, event-driven, randomized, multicenter,
double-blind, placebo-controlled trial designed to evaluate whether
treatment with NEXLETOL reduces the risk of cardiovascular events
in patients with or who are at high risk for cardiovascular disease
with documented statin intolerance (inability to tolerate 2 or more
statins, one at a low dose) and elevated LDL-C levels (fasting
blood LDL-C ≥ 100 (2.6 mmol/L). The study, which includes over
14,000 patients at over 1,200 sites in 32 countries, accumulated
the targeted 1,620 primary major adverse cardiovascular events
(MACE-4) in August 2022.
Esperion TherapeuticsEsperion works hard to
make our medicines easy to get, easy to take and easy to have. We
discover, develop, and commercialize innovative medicines and
combinations to lower cholesterol, especially for patients whose
needs aren’t being met by the status quo. Our entrepreneurial team
of industry leaders is inclusive, passionate and resourceful. We
are singularly focused on managing cholesterol so you can improve
your health easily. For more information, please visit
www.esperion.com and follow us on Twitter at
www.twitter.com/EsperionInc.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding marketing strategy and commercialization
plans, current and planned operational expenses, future operations,
commercial products, clinical development, including the timing,
designs and plans for the CLEAR Outcomes study and its results,
plans for potential future product candidates, financial condition
and outlook, including expected cash runway, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the impact of the ongoing
COVID-19 pandemic on our business, revenues, results of operations
and financial condition, the net sales, profitability, and growth
of Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, and the
risks detailed in Esperion’s filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact:Esperion Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024